How Does Modafinil Treat Sleep Apnea?

To use modafinil effectively for treating sleep apnea, you must follow the medication guide carefully. Take the medicine at the recommended dose and duration as directed by your doctor. For some people, taking the medication with or without food is recommended. Those with obstructive sleep apnea should take the medication by mouth. If you choose to use modafinil for sleep apnea, you must also continue your other treatment.

Side effects

In a study, untreated men with mild to moderate OSA were randomize to receive 200 mg of modafinil or a matching placebo for two weeks. The patients were evaluated using the Epworth Sleepiness Scale. Modafinil was more effective than placebo in improving ESS scores, and two-thirds of the patients had normalized ESS scores after the treatment. The results were analyzed using a mix model analysis of variance.

In a placebo-controlled clinical trial, some patients experienced withdrawal from modafinil after nine weeks of treatment. They did not experience withdrawal symptoms, but their sleepiness returned. Similarly, a person taking the drug may experience a rash or multiorgan hypersensitivity reaction. It is important to monitor for symptoms and to discontinue the drug if a patient experiences either of these side effects.

Dosing

The dosage of modafinil for OSA is based on a two-week randomized controlled trial. The study included a total of 132 untreated men with mild to moderate OSA (as measured by the Epworth Sleepiness Scale). The study included a minimum of two weeks’ washout between treatment groups. The results were analyze using a mix model analysis of variance.

A doctor’s prescription should specify the dosage and frequency. If you are taking the drug to treat sleep apnea as a result of shift work, the recommended dose is one tablet per day, preferably taken with food. Dosage may vary according to the severity of your symptoms. In addition, the drug may be take with or without food. Always follow the doctor’s instructions to avoid possible side effects.

Inclusion of studies

A recent study included a randomize trial evaluating the use of modafinil for daytime sleepiness in Japanese patients with OSAS. They were also receiving optimal nasal continuous positive airway pressure therapy (CPAP). The outcomes were the baseline-week-4 change in the total score of the ESS, sleep latency on the maintenance of wakefulness test, and Pittsburgh Sleep Quality Index.

The adverse effects associated with modafinil include a range of cardiovascular, respiratory, and gastrointestinal (GI) side effects. These may be severe and sometimes require hospitalization. Researchers have not determined which types of ADR are likely to occur. The most common side effects reported in the modafinil group include insomnia, headaches, and palpitations. Neither group reported severe adverse events.

Safety

A new study on the role of Modalert in the treatment of narcolepsy, OSA, and SWD shows promising results. Narcolepsy, shift work sleep disorder, and obstructive sleep apnea can all be treated with Modalert 200. You can stop becoming sleepy during the day by using Modvigil. The drug significantly reduces the severity of sleep apnea in patients with these conditions. However, it should be noted that modafinil has a few risks. In addition to being addictive, modafinil may cause side effects, including an increased risk of narcolepsy and a higher risk of cardiovascular disease. Despite the promising results, patients should remain on medication for the duration of the study.

There are several risks associate with modafinil, including an increase risk of hypnagogic hallucinations, Tourette’s syndrome, insomnia, and hyperactivity. Some users may experience increase leukopenia, which can be resolve without medical intervention. Three out of 38 girls aged 12 and older who received modafinil experienced dysmenorrhea. In both cases, the risk of developing sleep apnea is high.

Efficacy

In a 12-month open-label, flexible-dose study, modafinil significantly improved the ESS total score in subjects with obstructive sleep apnea. The ESS total score decreased by 6.6 minutes, and the mean sleep latency on the maintenance of wakefulness test (MWT) was 2.8 minutes shorter.